Nov 04, 2020 7:00am EST Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Oct 28, 2020 8:00am EDT Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020
Sep 20, 2020 11:00am EDT Pieris Pharmaceuticals Presents Updated Data from Phase 1 Monotherapy and Atezolizumab Combination Studies of 4-1BB/HER2 Bispecific PRS-343 at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
Aug 10, 2020 7:00am EDT Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Aug 10, 2020 6:30am EDT Pieris and Lilly Enter Into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 With Ramucirumab and Paclitaxel in Gastric Cancer
Aug 03, 2020 8:00am EDT Pieris Pharmaceuticals to Host Second Quarter 2020 Investor Call and Corporate Update on August 10, 2020
Jul 23, 2020 8:00am EDT Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020
